This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Shipping:
Room Temperature Shipping
Qinlock (ripretinib) is shipped using standard delivery methods while maintaining a controlled room temperature of 15°C to 25°C to preserve the medication’s stability and effectiveness.
Disease Indications:
• Advanced Gastrointestinal Stromal Tumor (GIST, after prior treatment with ≥3 kinase inhibitors)
Manufacturer:
Deciphera Pharmaceuticals, Inc.
Usage:
Oral
Qinlock (ripretinib)
General Description:
Qinlock (ripretinib) is an oral targeted therapy indicated for adults with advanced gastrointestinal stromal tumors (GIST) who have previously undergone treatment with at least three different kinase inhibitors, including imatinib, sunitinib, and regorafenib. Qinlock works by selectively inhibiting key kinases involved in tumor growth, helping to slow the progression of cancer and improve patient outcomes.
The medication is taken orally, with dosing schedules personalized by your oncologist depending on your health status and previous treatments.
Getting Qinlock (ripretinib) in India:
Qinlock (ripretinib) is approved in several countries, including the United States, Europe, Canada, and Australia. Although not yet commercially available in India, eligible patients can access it through the Named Patient Program (NPP) under the guidance of a qualified physician.
MitoGENE assists Indian patients in obtaining Qinlock (ripretinib) safely and compliantly. Our team handles all required documentation, import permissions, and logistics to ensure smooth delivery under India’s regulatory framework.
If you or a loved one is dealing with advanced GIST, MitoGENE can guide you through a secure and patient-focused process to access Qinlock (ripretinib).
Medicine Approved By:
• Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Health Canada
• Therapeutic Goods Administration (TGA, Australia)
Available Dosage Form & Package:
• Single bottle containing 90 tablets of 50 mg
How to Access Qinlock (ripretinib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Qinlock (ripretinib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
